InsidersTradesSigma
Follow the Illumina, INC. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Illumina, INC. has logged 360 insider filings. Market capitalisation: €34bn. The latest transaction was disclosed on 27 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Meister Keith A.. All data is free.
360
Insider Decl.
n/a
Thresholds
€1m
5 ops.
Buy Volume
€337m
114 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Illumina, INC. Buy (bullish), based on 19 analysts. Average price target: US$198.89.
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,801 of 29,055 companies
59.6
score / 100
Value40
Quality79
FCF yld2.9%
Earn yld2.6%
EV/EBITDA23.9x
ROE32%
Gross mgn66%
Net mgn20%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
Declarations360 total
200,000 shares@ US$224.84Common Stock, par value $0.01 per shareSEC144:0001011438-26-000555
54,309 shares@ US$227.670.036% mcap3.0% of flowCommon StockSEC:0001193125-26-371756:8
92,776 shares@ US$225.260.061% mcap5.1% of flowCommon StockSEC:0001193125-26-371756:0
38,201 shares@ US$226.130.025% mcap2.1% of flowCommon StockSEC:0001193125-26-371756:1
42 shares@ US$226.790.0000% mcap0.0% of flowCommon StockSEC:0001193125-26-371756:2
38,213 shares@ US$224.720.025% mcap2.1% of flowCommon StockSEC:0001193125-26-371756:3
53,123 shares@ US$225.690.035% mcap2.9% of flowCommon StockSEC:0001193125-26-371756:4
14,782 shares@ US$226.500.0098% mcap0.8% of flowCommon StockSEC:0001193125-26-371756:5
425 shares@ US$227.220.0003% mcap0.0% of flowCommon StockSEC:0001193125-26-371756:6
4,873 shares@ US$226.740.0033% mcap0.3% of flowCommon StockSEC:0001193125-26-371756:7
24,363 shares@ US$228.640.016% mcap1.4% of flowCommon StockSEC:0001193125-26-371756:9
16,990 shares@ US$229.720.011% mcap1.0% of flowCommon StockSEC:0001193125-26-371756:10
28,439 shares@ US$230.540.019% mcap1.6% of flowCommon StockSEC:0001193125-26-371756:11
9,405 shares@ US$231.230.0064% mcap0.5% of flowCommon StockSEC:0001193125-26-371756:12
300,000 shares@ US$223.220.20% mcap18.5% of flowCommon Stock, par value $0.01 per shareSEC144:0001011438-26-000554
250,000 shares@ US$213.240.17% mcap18.1% of flowCommon Stock, par value $0.01 per shareSEC144:0001315863-26-000610
5,693 shares@ US$218.460.0039% mcap0.4% of flowCommon StockSEC:0001193125-26-361476:15
6,821 shares@ US$213.810.0045% mcap0.5% of flowCommon StockSEC:0001193125-26-361476:20
15,263 shares@ US$216.880.010% mcap1.0% of flowCommon StockSEC:0001193125-26-361476:13
19,884 shares@ US$202.370.013% mcap1.3% of flowCommon StockSEC:0001193125-26-361476:0
57,544 shares@ US$203.160.037% mcap3.7% of flowCommon StockSEC:0001193125-26-361476:1
4,759 shares@ US$204.160.0030% mcap0.3% of flowCommon StockSEC:0001193125-26-361476:2
12,813 shares@ US$205.000.0082% mcap0.8% of flowCommon StockSEC:0001193125-26-361476:3
1,132 shares@ US$207.650.0007% mcap0.1% of flowCommon StockSEC:0001193125-26-361476:4
3,563 shares@ US$208.550.0023% mcap0.2% of flowCommon StockSEC:0001193125-26-361476:5
25 of 360 declarations
关于 Illumina, INC.
Illumina, Inc. 是一家领先的基因组学技术公司，在纳斯达克（美国）上市，股票代码为 ILMN。该公司于1998年在加利福尼亚州圣迭戈成立，其业务围绕 DNA 测序、微阵列技术以及相关的软件和耗材展开。其全球总部仍设在圣迭戈，商业足迹遍布全球，在美洲、欧洲和亚太地区均设有运营和客户支持部门。（[illumina.com](https://www.illumina.com/company/about-us.html?utm_source=openai)) Illumina 的商业模式以向学术研究机构、制药公司、生物技术公司、医院和分子诊断参与者销售测序平台、试剂、耗材、分析工具和服务为中心。该公司历史上与合成测序 (SBS) 技术紧密相关，该技术已成为行业标准，并且公司持续投资于更高的通量、更好的准确性和更低的每样本成本。这一技术基础使 Illumina 在高通量测序领域拥有强大的竞争地位，尽管市场竞争激烈，包括来自长读长测序专家和其他新兴平台。（[illumina.com](https://www.illumina.com/content/dam/illumina-marketing/documents/company/illumina-corporate-fact-sheet-072214.pdf)) Illumina 的产品组合涵盖测序仪器、文库制备试剂盒、化学品和解释软件。NovaSeq X 等下一代系统和 DRAGEN 等软件产品是其战略的核心，同时越来越关注临床基因组学、精准肿瘤学、转化研究和多组学工作流程。该公司还扩大了其临床肿瘤学产品，包括在监管批准后扩大了 TSO Comprehensive 的报销范围，从而提高了临床医生和患者的可及性。（[investor.illumina.com](https://investor.illumina.com/news/press-release-details/2026/Illumina-unveils-roadmap-of-groundbreaking-NovaSeq-X-advancements-in-data-quality-output-speed-and-flexibility/default.aspx?utm_source=openai)) 从地理上看，Illumina 是一家总部位于美国的公司，拥有真正的国际收入和运营概况。它为160多个国家/地区的客户提供服务，并在多个地区设有办事处和商业团队。对于讲法语的投资者而言，这很重要，因为它分散了对单一市场的风险敞口，同时公司仍对实验室资本支出周期、公共卫生预算和当地监管发展敏感。（[illumina.com](https://www.illumina.com/company/about-us.html?utm_source=openai)) 近期亮点突显了新的创新推动。Illumina 于2026年2月5日公布了2025年全年业绩，并于2026年4月30日公布了2026年第一季度业绩，其中包括第一季度收入1.09 billion美元和新的1.5 billion美元股票回购授权。在2025年和2026年，该公司还宣布了在肿瘤学、5碱基解决方案、DRAGEN v4.5、NovaSeq X 改进以及旨在实现人工智能药物发现的合作方面的进展。总而言之，这些举措表明其战略重点是产品创新、运营杠杆和更广泛的临床应用。（[investor.illumina.com](https://investor.illumina.com/news/press-release-details/2026/Illumina-Reports-Financial-Results-for-Fourth-Quarter-and-Fiscal-Year-2025/default.aspx))
